Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction

Circulation

Volumn 99, Issue 9, 1999, Pages 1161-1164

  Ridker, Paul M ^a,b   Kundsin, Ruth B ^a   Stampfer, Meir J ^a   Poulin, Sharon ^a   Hennekens, Charles H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibodies; Atherosclerosis; Myocardial infarction; Proteins risk factors

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY RISK; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0033537632     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.9.1161     Document Type: Article

References (30)

1. Saikku P, Mattila K, Nieminen MS, Huttunen JK, Leinonen M, Ekman M-R, Mäkelä PH, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancer. 1988;2:983-986.
2. Thom DH, Grayston JT, Siscovick D, Way S-P, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992;268: 68-72.
3. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993; 87:1130-1134.
4. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang S-P, Szklo M, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med. 1993;95:499-504.
5. Thom DH, Wang S-P, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, Weiss NS. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb. 1991;11:547-551.
6. Mendall MA, Carrington D, Strachan DP, Patel P, Molineaux N, Levy J, Toosey T, Camm AJ, Northfield TC. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995;30:121-128.
7. Kuo CC, Shor A, Campbell L, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-849.
8. Campbell LA, O'Brien ER, Cappuccio AL, Kuo CC, Wang SP, Stewart D, Patton DL, Cummings PK, Grayston JT. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 1995;172:585-588.
9. Blasi F, Denti F, Erba M, Cosentini R, Raccanelli R, Rinaldi A, Fagetti L, Esposito G, Ruberti U, Allegra L. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol. 1996;34:2766-2769.
10. Ramirez JA, and the Chlamydia pneumoniae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 1996;125: 979-982.
11. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, Woods ML, Anderson JL. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555-1561.
12. Grayston JT. Chlamydia in atherosclerosis. Circulation. 1993;87: 1408-1409.
13. Gupta S. Chronic infection in the etiology of atherosclerosis: the case for Chlamydia pneumoniae. Clin Cardiol. 1997;20:829-836.
14. Ridker PM, Cushman M, Stampfer MJ, Tracey RP. Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
15. Saikku P, Leinonen M, Tendanen L, Linnanmäki E, Ekman M-R, Manninen V, Mänttäri M, Frick H, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273-278.
16. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala K, Laakso M. Association of Chlamydia pneumoniae and acute coronary heart disease in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J. 1996;17:682-688.
17. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
18. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97:1671-1674.
19. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
20. Wang SP, Grayston JT. Microimmunofluorescence serology in Chlamydia trachomatis. In: de la Maza LM, ed. The 1983 International Symposium on Medical Virology. New York, NY: Elsevier Science; 1984:87-118.
21. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992;15:757-763.
22. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
23. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
24. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
25. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.
26. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
27. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
28. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
29. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomized trial of roxithromycin in non-Q-wave coronary syndromes. ROXIS pilot study. Lancet. 1997;350:404-407.
30. Davidson M, Kuo C-C, Middaugh JP, Campbell LA, Wang S-P, Newman WP, Finley JC, Grayston JT. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998;98:628-633.